Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Acute Inflammatory Demyelinating Polyradiculoneuropathy Follow-up

  • Author: Tarakad S Ramachandran, MBBS, MBA, MPH, FAAN, FACP, FAHA, FRCP, FRCPC, FRS, LRCP, MRCP, MRCS; Chief Editor: Nicholas Lorenzo, MD, MHA, CPE  more...
 
Updated: Mar 25, 2016
 

Further Outpatient Care

Generally, all patients in whom AIDP is suspected should be admitted for further monitoring and treatment.

Patients who present with mild neurologic impairment after already reaching a plateau can be treated as outpatients with close supervision.

Upon discharge, patients require several follow-up visits to ensure that relapses do not occur and to help coordinate home-health services if necessary. Physical and occupational therapy, either in a long-term rehabilitation unit or at home, help many patients return more rapidly to their baseline level of activity.

Relapses occur (10-20%) following completion of plasma exchange, and these relapses frequently respond to a second course of treatment. Similarly, relapses that follow IVIG therapy also respond to a second course.

Next

Further Inpatient Care

Based on the severity of symptoms, patients with acute inflammatory demyelinating polyradiculoneuropathy (AIDP) may require further inpatient services.

  • Patients should have cardiac monitoring to confirm and treat arrhythmias.
  • Pulmonary function tests such as FVC and negative inspiratory pressure should be performed 3-4 times a day until a patient has reached a plateau for several days.
  • Transfer to an ICU is recommended for patients with worsening respiratory effort (ie, FVC < 20 mL/kg) or cardiac arrhythmias.
  • Physical therapy should be initiated early to help increase patient activity and mobility. Patients who do not recover quickly benefit by transfer to an inpatient rehabilitation center before returning home.
Previous
Next

Transfer

Transfer patients to the ICU when respiratory failure is impending or when cardiac arrhythmias are occurring.

Transfer patients to regional or tertiary hospitals if a community hospital does not have an ICU or is unable to provide IVIg or plasmapheresis therapy.

Previous
Next

Complications

Critically ill patients are susceptible to the same complications as other intubated patients, including pneumonia, sepsis, skin decubiti, deep venous thrombosis, and urinary tract infections. Patients with AIDP have some unique complications that may cause significant morbidity, the most common being pain, labile blood pressure, and increased sensitivity to cardiac medications.

Previous
Next

Prognosis

About 75% of patients have an excellent recovery and regain their premorbid condition. Some of these patients experience easy fatigability for many years.

Almost all of the remaining patients have mild or moderately severe impairment but remain independent in most functions. Residual complaints include dysesthesias, foot drop, and intrinsic hand muscle weakness.

Severe disability occurs in fewer than 5% of patients, who do not recover full independence. Patients with residual deficits are usually those who required mechanical intubation. Improvement is usually complete by 6 months. In more serious cases, recovery may continue for 18-24 months.

Death occurs in only 2-6% of patients and is usually due to cardiac arrest, ARDS, pulmonary embolism, severe bronchospasm, pneumonia, or sepsis.

About 10% of patients have a relapse 1-6 weeks after completing immunomodulatory therapy. These patients can be treated with a second course of immunomodulation.

Fewer than 1% of patients have AIDP 1 or more years after onset of symptoms. In some cases, the recurrence follows immunization. This recurrence differs from CIDP.

Sporadic cases of recurrent Guillain-Barré syndrome[19] and rare cases of recurrent Guillain-Barré syndrome after a long asymptomatic period[20] have been reported. Some authors consider recurrent Guillain-Barré syndrome a variant of CIDP, while others maintain that they are 2 different entities. Martic et al describe a patient who developed Guillain-Barré syndrome as a child and experienced a full relapse after 19 years with another innocuous episode 10 years later.[21]

Several prognostic factors have been identified, including the following:

  • In general, younger patients have a better prognosis than older patients. Those patients with more severe weakness and those who are intubated have a worse prognosis than those with milder weakness.
  • Diarrhea as an antecedent association often is associated with C jejuni infection. These patients may have a more prolonged recovery.
  • Early improvement in strength during treatment is associated with a more rapid recovery. Low compound muscle action potential (CMAP) amplitudes (< 20% of normal) are considered a bad prognostic indicator.

In spite of therapy with plasma exchange or IVIG, the decrease in mortality has often been attributed to improved aggressive supportive treatment than to any drug treatment. This has included close monitoring with the avoidance of hypoxia, pain, and arrhythmogenic stimuli.

In the presence of dysautonomia, hypoxia can trigger cardiac arrhythmias. Tracheal suction can also at times result in cardiac arrhythmias. Ideally, these patients should be given extra oxygen before tracheal toilet.

Subcutaneous heparin to avoid venous thromboembolism, treatment of pain with analgesics including narcotics, treatment of hypotension and hypertension, as the case be and treatment of severe bradyarrhythmia all go a long way in decreasing mortality. Carbamazepine and gabapentin may help.

Persistent fatigue following Guillain-Barré syndrome is common and may be helped by a graded exercise program. C jejuni is often treated with a course of erythromycin.

Hyponatremia is due to inappropriate antidiuretic hormone secretion (SIADH) is best managed by fluid restriction coupled by the avoidance of hyponatremic fluids. Need for immunization should be reviewed on an individual basis.

Previous
Next
 
Contributor Information and Disclosures
Author

Tarakad S Ramachandran, MBBS, MBA, MPH, FAAN, FACP, FAHA, FRCP, FRCPC, FRS, LRCP, MRCP, MRCS Professor Emeritus of Neurology and Psychiatry, Clinical Professor of Medicine, Clinical Professor of Family Medicine, Clinical Professor of Neurosurgery, State University of New York Upstate Medical University; Neuroscience Director, Department of Neurology, Crouse Irving Memorial Hospital

Tarakad S Ramachandran, MBBS, MBA, MPH, FAAN, FACP, FAHA, FRCP, FRCPC, FRS, LRCP, MRCP, MRCS is a member of the following medical societies: American College of International Physicians, American Heart Association, American Stroke Association, American Academy of Neurology, American Academy of Pain Medicine, American College of Forensic Examiners Institute, National Association of Managed Care Physicians, American College of Physicians, Royal College of Physicians, Royal College of Physicians and Surgeons of Canada, Royal College of Surgeons of England, Royal Society of Medicine

Disclosure: Nothing to disclose.

Coauthor(s)

Richard A Sater, MD, PhD, MD, PhD 

Richard A Sater, MD, PhD, MD, PhD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Neurology, American Medical Association, American Society of Neuroradiology

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Glenn Lopate, MD Associate Professor, Department of Neurology, Division of Neuromuscular Diseases, Washington University School of Medicine; Consulting Staff, Department of Neurology, Barnes-Jewish Hospital

Glenn Lopate, MD is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, Phi Beta Kappa

Disclosure: Nothing to disclose.

Chief Editor

Nicholas Lorenzo, MD, MHA, CPE Founding Editor-in-Chief, eMedicine Neurology; Founder and CEO/CMO, PHLT Consultants; Chief Medical Officer, MeMD Inc

Nicholas Lorenzo, MD, MHA, CPE is a member of the following medical societies: Alpha Omega Alpha, American Association for Physician Leadership, American Academy of Neurology

Disclosure: Nothing to disclose.

References
  1. HAYMAKER WE, KERNOHAN JW. The Landry-Guillain-Barré syndrome; a clinicopathologic report of 50 fatal cases and a critique of the literature. Medicine (Baltimore). 1949 Feb. 28(1):59-141. [Medline].

  2. Krucke W. Die primar-entzundliche polyneuritis unbekannter ursache. Handbuch des speziellen pathologischen anatomie und histologie. 1955. Berlin, Springer-Verlag:

  3. WAKSMAN BH, ADAMS RD. Allergic neuritis: an experimental disease of rabbits induced by the injection of peripheral nervous tissue and adjuvants. J Exp Med. 1955 Aug 1. 102(2):213-36. [Medline].

  4. Nachamkin I, Barbosa PA, Ung H, Lobato C, Rivera AG, Rodriguez P. Patterns of Guillain-Barre syndrome in children: results from a Mexican population. Neurology. 2007 Oct 23. 69(17):1665-71. [Medline].

  5. Ropper AH. Unusual clinical variants and signs in Guillain-Barre syndrome. Arch Neurol. 1986 Nov. 43(11):1150-2. [Medline].

  6. Nagashima T, Koga M, Odaka M, Hirata K, Yuki N. Continuous spectrum of pharyngeal-cervical-brachial variant of Guillain-Barré syndrome. Arch Neurol. 2007 Oct. 64(10):1519-23. [Medline].

  7. Ladhani SN, O'Connor C, Kirkbride H, Brooks T, Morgan D. Outbreak of Zika virus disease in the Americas and the association with microcephaly, congenital malformations and Guillain-Barré syndrome. Arch Dis Child. 2016 Mar 14. [Medline].

  8. Tse AC, Cheung RT, Ho SL, Chan KH. Guillain-Barré syndrome associated with acute hepatitis E infection. J Clin Neurosci. 2012 Jan 26. [Medline].

  9. Wagner JC, Bromberg MB. HIV infection presenting with motor axonal variant of Guillain-Barré Syndrome. J Clin Neuromuscul Dis. 2007 Dec. 9(2):303-5. [Medline].

  10. Willison HJ. The immunobiology of Guillain-Barre syndromes. J Peripher Nerv Syst. 2005 Jun. 10(2):94-112. [Medline].

  11. Park SJ, Pai KS, Kim JH, Shin JI. The role of interleukin 6 in the pathogenesis of hyponatremia associated with Guillain-Barré syndrome. Nefrologia. 2012 Jan 27. 32(1):114. [Medline].

  12. Kaida K, Kamakura K, Ogawa G, Ueda M, Motoyoshi K, Arita M. GD1b-specific antibody induces ataxia in Guillain-Barre syndrome. Neurology. 2008 Jul 15. 71(3):196-201. [Medline].

  13. Cornblath DR. Electrophysiology in Guillain-Barré syndrome. Ann Neurol. 1990. 27 Suppl:S17-20. [Medline].

  14. Matsumoto H, Hanajima R, Terao Y, Hashida H, Ugawa Y. Cauda equina conduction time in Guillain-Barre syndrome. J Neurol Sci. 2015 Apr. 15. 351(1-2):187-90.

  15. Umapathi T. Li Z, Verma K, Yuki N. Sural-sparing is seen in axonal as well as demyelinating forms of Guillain-Barre syndrome. Clin Neurophysiol. 2015 Feb. 9. pii S1388-2457(15):00072-3.

  16. Jin K, Takeda A, Shiga Y, Sato S, Ohnuma A, Nomura H. CSF tau protein: a new prognostic marker for Guillain-Barré syndrome. Neurology. 2006 Oct 24. 67(8):1470-2. [Medline].

  17. Alshekhlee A, Hussain Z, Sultan B, Katirji B. Immunotherapy for Guillain-Barré syndrome in the US hospitals. J Clin Neuromuscul Dis. 2008 Sep. 10(1):4-10. [Medline].

  18. Hou HQ, Miao J, Feng XD, Han M, Song XJ, Guo L. Changes in lymphocyte subsets in patients with Guillain-Barre syndrome treated with immunoglobulin. BMC Neurol. 2014 Oct. 15. 14:202.

  19. Grand'Maison F, Feasby TE, Hahn AF, Koopman WJ. Recurrent Guillain-Barré syndrome. Clinical and laboratory features. Brain. 1992 Aug. 115 ( Pt 4):1093-106. [Medline].

  20. Wijdicks EF, Ropper AH. Acute relapsing Guillain-Barré syndrome after long asymptomatic intervals. Arch Neurol. 1990 Jan. 47(1):82-4. [Medline].

  21. Martic V, Lepic T. Recurrence of childhood Guillain-Barré syndrome after a long asymptomatic interval: a case report. J Clin Neuromuscul Dis. 2007 Sep. 9(1):256-61. [Medline].

  22. Souayah N, Nasar A, Suri MFK, Qureshi A. National Trends in Hospital Outcomes Among Patients with Guillain-Barre Syndrome Requiring Mechanical Ventilation. Journal of Clinical Neuromuscular Disease. 2008. 10(1):24-28.

  23. Frenzen PD. Economic cost of Guillain-Barré syndrome in the United States. Neurology. 2008 Jul 1. 71(1):21-7. [Medline].

  24. Asbury AK. Diagnostic considerations in Guillain-Barre syndrome. Ann Neurol. 1981. 9 Suppl:1-5. [Medline].

  25. Ascherio A, Bermudez CS, Garcia D. Outbreak of buckthorn paralysis in Nicaragua. J Trop Pediatr. 1992 Apr. 38(2):87-9. [Medline].

  26. Berlit P, Rakicky J. The Miller Fisher syndrome. Review of the literature. J Clin Neuroophthalmol. 1992 Mar. 12(1):57-63. [Medline].

  27. Chiba A, Kusunoki S, Obata H. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barre syndrome: clinical and immunohistochemical studies. Neurology. 1993 Oct. 43(10):1911-7. [Medline].

  28. Crino PB, Zimmerman R, Laskowitz D. Magnetic resonance imaging of the cauda equina in Guillain-Barre syndrome. Neurology. 1994 Jul. 44(7):1334-6. [Medline].

  29. Dwyer JM. Manipulating the immune system with immune globulin. N Engl J Med. 1992 Jan 9. 326(2):107-16. [Medline].

  30. Feasby TE. Axonal Guillain-Barre syndrome. Muscle Nerve. 1994 Jun. 17(6):678-9. [Medline].

  31. FISHER M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med. 1956 Jul 12. 255(2):57-65. [Medline].

  32. French Cooperative Group on Plasma Exchange in Guillain-Barre syndrome. Efficiency of plasma exchange in Guillain-Barre syndrome: role of replacement fluids. French Cooperative Group on Plasma Exchange in Guillain-Barre syndrome. Ann Neurol. 1987 Dec. 22(6):753-61. [Medline].

  33. Guillain G, Barre JA, Strohl A. Sur un syndrome de radiculo-nevrite avec hyperalbuminose du liquide cephalo-rachidien sans reaction cellulaire. Bulletins et memories de la Societe Medicale des Hopitaux de Paris. 1916. 40:1462.

  34. Guillain-Barré Syndrome Study Group. Plasmapheresis and acute Guillain-Barre syndrome. Neurology. 1985 Aug. 35(8):1096-104. [Medline].

  35. Hughes RAC. Guillain-Barre Syndrome. 1990.

  36. Irani DN, Cornblath DR, Chaudhry V. Relapse in Guillain-Barre syndrome after treatment with human immune globulin. Neurology. 1993 May. 43(5):872-5. [Medline].

  37. Landry O. Note sur la paralysis ascendante aigue. Gazette Hebdomadaire. 1859. 6:472.

  38. Leong H, Stachnik J, Bonk ME, Matuszewski KA. Unlabeled uses of intravenous immune globulin. Am J Health Syst Pharm. 2008 Oct 1. 65(19):1815-24. [Medline].

  39. McGrogan A, Madle GC, Seaman HE, de Vries CS. The Epidemiology of Guillain-Barré Syndrome Worldwide. A Systematic Literature Review. Neuroepidemiology. 2008 Dec 17. 32(2):150-163. [Medline].

  40. McKhann GM, Cornblath DR, Griffin JW. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol. 1993 Apr. 33(4):333-42. [Medline].

  41. Osterman PO, Fagius J, Safwenberg J. Early relapse of acute inflammatory polyradiculoneuropathy after successful treatment with plasma exchange. Acta Neurol Scand. 1988 Apr. 77(4):273-7. [Medline].

  42. Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. Lancet. 1997 Jan 25. 349(9047):225-30. [Medline].

  43. Prineas JW. Acute idiopathic polyneuritis. An electron microscope study. Lab Invest. 1972 Feb. 26(2):133-47. [Medline].

  44. Ropper AH. Further regional variants of acute immune polyneuropathy. Bifacial weakness or sixth nerve paresis with paresthesias, lumbar polyradiculopathy, and ataxia with pharyngeal-cervical-brachial weakness. Arch Neurol. 1994 Jul. 51(7):671-5. [Medline].

  45. Ropper AH, Wijdicks EFM, Truax BT. Guillain-Barre Syndrome. Contemporary Neurology Series. 1991.

  46. Rostami AM, Sater RA. Guillain-Barre Syndrome. Neuroimmunology for the Clinician. 1997. 205-228.

  47. Sater RA, Rostami A. Treatment of Guillain-Barre syndrome with intravenous immunoglobulin. Neurology. 1998 Dec. 51(6 Suppl 5):S9-15. [Medline].

  48. van der Meche FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group. N Engl J Med. 1992 Apr 23. 326(17):1123-9. [Medline].

  49. Vriesendorp FJ, Mishu B, Blaser MJ. Serum antibodies to GM1, GD1b, peripheral nerve myelin, and Campylobacter jejuni in patients with Guillain-Barre syndrome and controls: correlation and prognosis. Ann Neurol. 1993 Aug. 34(2):130-5. [Medline].

  50. Vriesendorp FJ, Triggs WJ, Mayer RF. Electrophysiological studies in Guillain-Barre syndrome: correlation with antibodies to GM1, GD1B and Campylobacter jejuni. J Neurol. 1995 Jul. 242(7):460-5. [Medline].

  51. Willison HJ, Winer JB. Clinical evaluation and investigation of neuropathy. J Neurol Neurosurg Psychiatry. 2003 Jun. 74 Suppl 2:ii3-ii8. [Medline].

  52. Young RR, Asbury AK, Corbett JL. Pure pandysautonomia with recovery. Description and discussion of diagnostic criteria. Brain. 1975 Dec. 98(4):613-36. [Medline].

  53. Yuki N, Taki T, Inagaki F. A bacterium lipopolysaccharide that elicits Guillain-Barre syndrome has a GM1 ganglioside-like structure. J Exp Med. 1993 Nov 1. 178(5):1771-5. [Medline].

  54. Yuki N, Taki T, Takahashi M, Saito K, Yoshino H, Tai T, et al. Molecular mimicry between GQ1b ganglioside and lipopolysaccharides of Campylobacter jejuni isolated from patients with Fisher's syndrome. Ann Neurol. 1994 Nov. 36(5):791-3. [Medline].

  55. Ubogu ee. Inflammatory neuropathies: pathology, molecular markers and targets for specific therapeutic intervention. Acta Neuropathol. Epub 2015 Aug 12 - 2015 Oct. 130(4):445-68. [Full Text].

 
Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.